| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 6th January 2021 | Capital, Llc Armistice | 1,531,101 | Open or private purchase | $5.23 | $8,000,002.73 |
| 6th January 2021 | Capital, Llc Armistice | 0 | Open or private purchase | $0.00 | |
| 10th December 2020 | Christopher Ryan Sullivan | 5,095 | Open or private purchase | $2.28 | $11,606.41 |
| 10th December 2020 | James Archie Jr Harrell | 171 | Open or private purchase | $2.28 | $389.54 |
| 10th December 2020 | Garry Arthur Neil | 3,599 | Open or private purchase | $2.28 | $8,198.52 |
| 4th December 2020 | Capital, Llc Armistice | 5,400 | Open or private purchase | $4.13 | $22,302.00 |
| 4th December 2020 | Capital, Llc Armistice | 0 | Open or private purchase | $0.00 | |
| 3rd December 2020 | Capital, Llc Armistice | 20,000 | Open or private purchase | $2.44 | $48,800.00 |
| 3rd December 2020 | Capital, Llc Armistice | 0 | Open or private purchase | $0.00 | |
| 2nd December 2020 | Capital, Llc Armistice | 1,000 | Open or private purchase | $4.31 | $4,310.00 |
Cerecor
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
Ticker: CERC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1534120
Employees: 64
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Revenue From Related Parties of $100 Th for the period Jan 2019 to Dec 2019 in the context of C e r c611
Fundamentals
Cash at Carrying Value: $45 M (0%)
Inventory, Net: $12 Th (-42%)
Assets, Current: $50 M (183%)
Property, Plant and Equipment, Net: $2 M (20%)
Assets: $69 M (91%)
Accounts Payable, Current: $3 M (23%)
Liabilities, Current: $15 M (20%)
Other Liabilities, Noncurrent: $2 M (82%)
Liabilities: $19 M (23%)
Common Stock, Value, Issued: $75 Th (68%)
Common Stock, Shares, Issued: $75 M (68%)
Retained Earnings (Accumulated Deficit): $149 M (0%)
Stockholders' Equity (Parent): $51 M (0%)
Liabilities and Equity: $69 M (91%)
Revenue: $1 M (0%)
Cost of Revenue: $78 Th (-46%)
Sales and Marketing: $653 Th (-50%)
General and Administrative Expenses: $6 M (-30%)
Operating Income/Loss: $12 M (-72%)
Other Income, net: $1 M (-74%)
Provision for income taxes: $454 Th (-9%)
